• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ARCA biopharma Inc. (Amendment)

    2/7/24 1:08:47 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ABIO alert in real time by email
    SC 13G/A 1 arca13g020724.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.   2  )*

    ARCA Biopharma, INC. 
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
     00211Y506
     
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     706,930
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     706,930
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     706,930
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     4.9%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1(a). Name of Issuer:

     

    ARCA Biopharma, INC.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     10170 Church Ranch Way, Suite 100, Westminster, CO

    Item 2(a). Name of Person Filing:

     

    BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar - Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock, $0.001 par value
     
    Item 2(e). CUSIP Number:

      00211Y506


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned:  706,930


    (b) Percent of class: 4.9


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 706,930

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 706,930
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 7, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
     

    Get the next $ABIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/13/24 4:55:08 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:01 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    SEC Filings

    View All

    ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/13/24 4:02:39 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/5/24 5:18:25 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 425 filed by ARCA biopharma Inc.

    425 - ARCA biopharma, Inc. (0000907654) (Subject)

    8/26/24 7:53:54 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Leadership Updates

    Live Leadership Updates

    View All

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna

    4/25/24 4:15:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Financials

    Live finance-specific insights

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/13/24 4:57:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D filed by ARCA biopharma Inc.

    SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/6/24 5:08:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by ARCA biopharma Inc.

    SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)

    4/29/24 7:28:44 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care